Dublin, July 10, 2019 (GLOBE NEWSWIRE) -- The "CB-839" report has been added to ResearchAndMarkets.com's offering.

Cancer cells are known to rely on glycolysis as an energy source. CB-839 (Calithera Biosciences) inhibits the glutaminase enzyme, reducing the ability of cancer cells to utilize glutamine in this biochemical pathway, thereby reducing cell proliferation and tumor growth.

If approved, CB-839 will be the first glutaminase inhibitor approved for the treatment of renal cell carcinoma (RCC). This novel mechanism of action could place CB-839 in a unique position in the RCC market and provide physicians with an alternative treatment option.

CB-839 is being investigated in combination with either Afinitor (everolimus; Novartis) or Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) for previously treated advanced RCC patients, suggesting it will not compete with the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) therapies being developed for first-line use.

CB-839 is being developed by Calithera Biosciences, a company that is yet to bring an oncology product to market. Due to Calithera's limited geographic scope, the author expects the company to look for partners to market CB-839 in Japan and the EU.

Key Topics Covered

1. Drug Overview
2. Product Profiles
3. CB-839: Renal cell carcinoma (RCC)

LIST OF FIGURES

• CB-839 for RCC - SWOT analysis
• The authors drug assessment summary of CB-839 for RCC
• CB-839 sales for RCC in the US, 2017-26

LIST OF TABLES

• CB-839 drug profile
• CB-839 Phase II trials in RCC
• CB-839 sales for RCC in the US ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/x0jjml

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Kidney Cancer Drugs 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.